Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Citations
10,501 citations
Cites background from "Dabrafenib in BRAF-mutated metastat..."
...Agents of particular interest for further testing include BRAF kinase inhibitors, as PTC frequently harbors the constitutively activating BRAF V600E mutation, and as these agents have already shown efficacy and been approved for use in BRAF mutant melanoma (1049-1051)....
[...]
4,602 citations
3,131 citations
Cites background from "Dabrafenib in BRAF-mutated metastat..."
...Though treatment with BRAFtargeted therapy alone provides limited durable disease control (Chapman et al., 2011; Hauschild et al., 2012), it is associated with favorable effects in the tumor microenvironment, including increased antigen (Boni et al., 2010) and HLA expression (Bradley et al., 2015),…...
[...]
2,457 citations
Additional excerpts
...Nausea 0 11 (21) 3 (6) 25 (46) 1 (2) 24 (44)...
[...]
...Night sweats 0 3 (6) 0 8 (15) 0 13 (24)...
[...]
...Fatigue 3 (6) 21 (40) 1 (2) 31 (57) 2 (4) 29 (53)...
[...]
...Elevated blood alkaline phosphatase 0 1 (2) 3 (6) 12 (22) 0 5 (9)...
[...]
...Hyperkeratosis 0 16 (30) 0 3 (6) 0 5 (9)...
[...]
2,144 citations
References
21,040 citations
20,760 citations
10,630 citations
9,785 citations
6,773 citations